These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12893407)

  • 21. Prescribing practices for the treatment of hepatitis C in a Veterans Affairs medical center.
    Mangin EF; Jones WN
    Am J Health Syst Pharm; 2004 Jul; 61(14):1479-82. PubMed ID: 15332696
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of bronchiolitis obliterans organizing pneumonia during standard treatment of hepatitis C with Peg-IFNα2b.
    Chung E; Park K; Kim JH; Han NI; Lee YS; Bae SH; Park CH
    Korean J Intern Med; 2017 Nov; 32(6):1098-1100. PubMed ID: 28823117
    [No Abstract]   [Full Text] [Related]  

  • 23. Pure red cell aplasia following pegylated interferon alpha treatment.
    Arcasoy MO; Rockey DC; Heneghan MA
    Am J Med; 2004 Oct; 117(8):619-20. PubMed ID: 15465516
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon alfa, peginterferon alfa and retinopathy.
    Prescrire Int; 2006 Apr; 15(82):61-2. PubMed ID: 16607695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon alfa-2a (40KD): a potent long-acting form of interferon alfa-2a for the treatment of hepatitis C.
    Modi MW; Lamb MW; Shiomi M
    Adv Exp Med Biol; 2003; 519():59-67. PubMed ID: 12675208
    [No Abstract]   [Full Text] [Related]  

  • 26. Adverse response to pegylated interferon therapy in two patients with chronic hepatitis C.
    Thomas WL; Ramos F; Hospenthal DR
    Hawaii Med J; 2003 Aug; 62(8):163-4. PubMed ID: 14533347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hepatitis C therapy is not pleasant. Patients must be prepared!].
    MMW Fortschr Med; 2003 Jan; 145(3-4):57. PubMed ID: 12619237
    [No Abstract]   [Full Text] [Related]  

  • 28. Erythema Annulare Centrifugum in the Era of Triple Therapy With Boceprevir Plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection.
    di Meo N; Stinco G; Fadel M; Errichetti E; Trevisan G
    J Cutan Med Surg; 2015; 19(3):203-4. PubMed ID: 26060126
    [No Abstract]   [Full Text] [Related]  

  • 29. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.
    Kraus MR; Schäfer A; Csef H; Scheurlen M
    World J Gastroenterol; 2005 Mar; 11(12):1769-74. PubMed ID: 15793861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythema gyratum repens induced by pegylated interferon alfa for chronic hepatitis C.
    Rongioletti F; Fausti V; Parodi A
    Arch Dermatol; 2012 Oct; 148(10):1213-4. PubMed ID: 23069974
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 32. Rapid onset of ulcerative colitis after treatment with PEG-interferon plus ribavirin for chronic hepatitis C.
    Tursi A
    Inflamm Bowel Dis; 2007 Sep; 13(9):1189-90. PubMed ID: 17427238
    [No Abstract]   [Full Text] [Related]  

  • 33. [Sarcoidosis induced by therapy with pegylated interferon alfa-2a].
    Bruch-Gerharz D; Reifenberger J
    Hautarzt; 2006 Apr; 57(4):317-35. PubMed ID: 16523277
    [No Abstract]   [Full Text] [Related]  

  • 34. New advances in hepatitis C therapy.
    Proj Inf Perspect; 2000 Aug; (30):18-9. PubMed ID: 12171011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sarcoidosis associated with the treatment of hepatitis C: case report and Spanish literature review].
    Trullàs JC; Hernández-Marcet P; Bisbe J
    Med Clin (Barc); 2011 May; 136(14):649-50. PubMed ID: 21051060
    [No Abstract]   [Full Text] [Related]  

  • 36. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 37. Lupus syndrome, hypothyroidism and bullous skin lesions after interferon alfa therapy for hepatitis C in a haemodialysis patient.
    Pouthier D; Theissen F; Humbel RL
    Nephrol Dial Transplant; 2002 Jan; 17(1):174. PubMed ID: 11773492
    [No Abstract]   [Full Text] [Related]  

  • 38. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon α-2b and ribavirin in a patient with hepatitis C.
    Colomba C; Rubino R; Siracusa L; Mazzola G; Titone L
    J Antimicrob Chemother; 2012 Jan; 67(1):249-50. PubMed ID: 21965434
    [No Abstract]   [Full Text] [Related]  

  • 39. Blurred vision: cause? Retinopathy secondary to interferon treatment.
    Bowen DW; Vyas S
    Gut; 2006 Feb; 55(2):211, 251. PubMed ID: 16407386
    [No Abstract]   [Full Text] [Related]  

  • 40. Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.
    Vartany E; Caldwell CA; Trow TK
    Heart Lung; 2008; 37(2):153-6. PubMed ID: 18371508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.